🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06696638
Recruiting Not applicable

Physiological Effects of Lung Impedance Tomography-Guided and Plat Pressure-Guided Phigh During APRV in Patients With ARDS

NCT06696638 · tracked via the Priya Life Science China tracker
Sponsor
XiaoJing Zou,MD
Phase
Not applicable
Started
2025-01-01
Last updated
2025-01-06

Condition(s) studied

ARDS: Acute Respiratory Distress Syndrome

Investigational drug(s) / intervention(s)

EIT-guided Phigh settings during APRV

EIT-guided Phigh settings during APRV: The Phigh level selected for the patients in the Intervention group was the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung.

Study summary

This study aims to investigate the effects of EIT-guided and Pplat-guided Phigh settings on regional ventilation and perfusion in ARDS patients during APRV, while also examining the impact of different Phigh settings on gas exchange, respiratory mechanics, and hemodynamics.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with ARDS according to the 2023 global new definition of ARDS. * Age ≥ 18 years. Exclusion Criteria: * Severe chronic obstructive pulmonary disease, severe asthma, pulmonary bullae, pneumothorax, subcutaneous emphysema, mediastinal emphysema, etc. · Contraindications for EIT, such as chest wound dressing, pacemaker implantation, defibrillator use, etc. * Pulmonary interstitial disease. * Uncorrected shock of various types. * Intracranial hypertension. * Pregnant and postpartum women.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Wuhan Union hospital Wuhan Hubei Recruiting

More XiaoJing Zou,MD trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06696638 on ClinicalTrials.gov ↗ ← All trials in China